Reply to “Activity of Fosfomycin on Clinical Isolates of *Campylobacter jejuni* and *Campylobacter coli* of Enteric Origin”

Juan Aguilar-Company,^a Ibai Los-Arcos,^a Carlos Pigrau,^{a,b} Benito Almirante^{a,b}

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain^a; Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain^b

We thank Antonio Sorlózano-Puerto, José María Navarro-Marí, and José Gutiérrez-Fernández for their comment on our paper (1, 2) and greatly appreciate their data on fosfomycin susceptibility in *Campylobacter* species isolates. To our knowledge, this is the first report on *Campylobacter* species susceptibility to fosfomycin since 1995 (3). As we stated in the Discussion, data on rates of resistance to fosfomycin in *Campylobacter* spp. are scarce and “further studies are needed to establish MIC break-points and define resistance rates in different geographical areas”; therefore, any information is of great value. Given their findings, we emphasize that determining the MIC of fosfomycin is crucial previous to deciding on its use in the therapy of difficult-to-treat *Campylobacter* species infections.

Citation Aguilar-Company J, Los-Arcos I, Pigrau C, Almirante B. 2017. Reply to “Activity of fosfomycin on clinical isolates of *Campylobacter jejuni* and *Campylobacter coli* of enteric origin.” *Antimicrob Agents Chemother* 61:e02448-16. <https://doi.org/10.1128/AAC.02448-16>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Juan Aguilar-Company, juanaguilarcompany@gmail.com, or Carlos Pigrau, cpigrau@vhebron.net.

This is a response to a letter by Sorlózano-Puerto et al. (<https://doi.org/10.1128/AAC.02317-16>).

REFERENCES

1. Aguilar-Company J, Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Larrosa MN, Rodríguez-Garrido V, Sihuay-Diburga D, Almirante B. 2016. Potential use of fosfomycin-tromethamine for treatment of recurrent *Campylobacter* species enteritis. *Antimicrob Agents Chemother* 60:4398–4400. <https://doi.org/10.1128/AAC.00447-16>.
2. Sorlózano-Puerto A, Navarro-Marí JM, Gutiérrez-Fernández J. 2017. Activity of fosfomycin on clinical isolates of *Campylobacter jejuni* and *Campylobacter coli* of enteric origin. *Antimicrob Agents Chemother* 61:e02317-16. <https://doi.org/10.1128/AAC.02317-16>.
3. Gomez-Garcés JL, Cogollos R, Alos JL. 1995. Susceptibilities of fluoroquinolone-resistant strains of *Campylobacter jejuni* to 11 oral antimicrobial agents. *Antimicrob Agents Chemother* 39:542–544. <https://doi.org/10.1128/AAC.39.2.542>.